Novel options for the treatment of castration-resistant prostate cancer

被引：12

作者：

Ohlmann, Carsten-H. ^{[1
]}

Merseburger, Axel S. ^{[2
]}

Suttmann, Henrik ^{[3
]}

Schilling, David ^{[4
]}

Trojan, Lutz ^{[5
]}

Kempkensteffen, Carsten ^{[6
]}

Corvin, Stefan ^{[7
]}

Mathers, Michael J. ^{[8
]}

Bastian, Patrick J. ^{[9
]}

机构：

[1] Univ Saarland, Dept Urol, D-66421 Homburg, Germany

[2] Hannover Med Sch, Dept Urol, D-3000 Hannover, Germany

[3] Urologikum Hamburg, Hamburg, Germany

[4] Univ Tubingen, Dept Urol, Tubingen, Germany

[5] Heidelberg Univ, Dept Urol, Med Fac Mannheim, D-6800 Mannheim, Germany

[6] Univ Med Berlin, Dept Urol, Charite, Berlin, Germany

[7] Fachzentrum Urol Eggenfelden, Eggenfelden, Germany

[8] PandaMED Remscheid, Remscheid, Germany

[9] Univ Munich, Urol Klin & Poliklin, Klinikum Univ Campus Grosshadern, Munich, Germany

来源：

WORLD JOURNAL OF UROLOGY | 2012年 / 30卷 / 04期

关键词：

Castration-resistant prostate cancer; Abiraterone; MDV3100; Zibotentan; Denosumab; Alpharadin; MITOXANTRONE PLUS PREDNISONE; RANDOMIZED PHASE-II; EVERY; 3; WEEKS; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; SIPULEUCEL-T; TUMOR PROGRESSION; CONTROLLED-TRIAL; CLINICAL-TRIAL; DOCETAXEL;

D O I：

10.1007/s00345-011-0796-7

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

引用

下载

页码：495 / 503

页数：9

共 50 条

[31] A Novel Mechanism to Drive Castration-Resistant Prostate Cancer
Kaochar, Salma
Mitsiades, Nicholas
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2018, 29 (06): : 366 - 368
[32] DIETHYLSTILBESTROL IN CASTRATION-RESISTANT PROSTATE CANCER OESTROGENS IN CASTRATION-RESISTANT PROSTATE CANCER: BACK TO THE FUTURE?
Sartor, Oliver
BJU INTERNATIONAL, 2012, 110 (11B) : E736 - E736
[33] The resurgence of estrogens in the treatment of castration-resistant prostate cancer
Moorthy, H. Krishna
Prabhu, G. G. Laxman
Venugopal, P.
INDIAN JOURNAL OF UROLOGY, 2019, 35 (03) : 189 - 196
[34] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
Mostaghel, Elahe A.
CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
[35] Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer
Lee, Patrick
Aragon-Ching, Jeanny B.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (10) : 1040 - 1045
[36] Monitoring of treatment for metastatic castration-resistant prostate cancer
Hinz, Stefan
AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
[37] Apalutamide for the treatment of patients with castration-resistant prostate cancer
Hauke, R.
DRUGS OF TODAY, 2018, 54 (10) : 585 - 590
[38] New Developments in the Treatment of Castration-Resistant Prostate Cancer
Higano, Celestia S.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (5.5): : 773 - 776
[39] The role of enzalutamide in the treatment of castration-resistant prostate cancer
Rawlinson, Alex
Mohammed, Aza
Miller, Marek
Kunkler, Roger
FUTURE ONCOLOGY, 2012, 8 (09) : 1073 - 1081
[40] Treatment Approaches for Nonmetastatic Castration-Resistant Prostate Cancer
Yildizhan, Mehmet
Gemalmaz, Hakan
Ertek, Mehmet Sirin
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2015, 14 (02): : 120 - 127

← 1 2 3 4 5 →